Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

← Obstetrics and gynaecology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Postpartum haemorrhage and massive transfusion

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Treat ongoing bleeding and shock together

Postpartum haemorrhage can progress rapidly while visual estimates and initial blood tests understate its severity.

Action: Call the obstetric and anaesthetic teams, quantify loss, assess ABC, obtain two large-bore intravenous lines and urgent bloods, activate haemorrhage support when needed, and treat tone, trauma, tissue and thrombin in parallel.

Overview

Recognise significant postpartum bleeding early, coordinate resuscitation with cause-directed haemostasis, and use uterotonics and blood components safely.

Postpartum haemorrhage is a clinical emergency defined by timing, amount and consequences of bleeding. RCOG traditionally describes primary PPH as at least 500 mL within twenty-four hours, with major PPH exceeding 1,000 mL. WHO's 2025 diagnostic criteria support treatment at measured loss of at least 300 mL with abnormal haemodynamics, or at least 500 mL, whichever occurs first. Operational staging varies between pathways. No volume label should delay intervention in someone with physiological compromise, pre-existing anaemia or limited reserve.

The central task is to stop bleeding while maintaining oxygen delivery and haemostasis. Uterotonics address deficient contraction, but they cannot repair a cervical tear or remove an abnormally adherent placenta safely. Transfusion replaces losses and deficits, but cannot compensate indefinitely for uncontrolled bleeding. Assigning simultaneous resuscitation and obstetric treatment roles prevents one stream from delaying the other.

Key points

  • Measure cumulative blood loss and interpret it alongside the woman's physiology.
  • Primary PPH occurs within twenty-four hours of birth; later abnormal bleeding follows a secondary-PPH assessment.

Aetiology

01

Tone and tissue

Atony prevents effective compression of placental-bed vessels. Overdistension, prolonged labour and infection can contribute; retained placental tissue or clot may prevent sustained contraction and must be addressed.

02

Trauma and thrombin

Genital tract tears, surgical injury, rupture and inversion can cause bleeding. Pre-existing or acquired coagulation abnormalities amplify loss and may coexist with a mechanical source.

Pathophysiology

  1. 1
    Failed physiological haemostasis

    After placental separation, contracting myometrium compresses vessels and clot formation stabilises haemostasis. Failure of either mechanism permits ongoing blood loss from a large vascular interface.

  2. 2
    Compensated then decompensated shock

    Pregnancy-related circulatory reserve may initially preserve blood pressure despite important loss. Continued bleeding eventually reduces organ perfusion, producing acidosis, impaired consciousness and cardiovascular collapse.

  3. 3
    Coagulopathy feedback

    Consumption, dilution, hypothermia and hypocalcaemia can impair coagulation as bleeding continues. Correcting these disturbances helps interrupt a cycle in which blood loss makes further bleeding harder to control.

Clinical features and red flags

Measure the cumulative loss

Collect and weigh blood-soaked materials and account for suction volumes, irrigation and amniotic fluid. State the running total aloud. Persistent modest bleeding can accumulate substantially, while internal bleeding after surgery may not appear in external collections.

Assess perfusion repeatedly

Review consciousness, skin perfusion, pulse, blood pressure, respiratory rate and urine output. Pregnancy can mask early circulatory deterioration. Worsening symptoms or a rising pulse deserve escalation before profound hypotension develops.

Differentiate the four Ts

Assess uterine tone, inspect the placenta for completeness, examine the genital tract and consider coagulation disorders. More than one mechanism can coexist: a repaired tear does not exclude concurrent atony, and coagulopathy may amplify any source.

Recognise contraindication-sensitive treatment

Ask specifically about hypertension or pre-eclampsia, asthma, cardiovascular disease, renal or hepatic impairment, sepsis and prior uterotonics. This short check changes medicine selection and helps avoid administering an ineffective or unsafe repeat treatment.

Red flags requiring action

  • Continuing brisk bleeding, rising pulse, falling pressure, confusion or poor perfusion requires emergency escalation regardless of measured volume.
  • A poorly contracted uterus suggests atony, but a firm uterus with ongoing loss requires examination for trauma or retained tissue.
  • Early severe coagulopathy or low fibrinogen should raise concern for abruption, AFE or other consumptive processes.

Investigations

  1. 01
    Full blood count and compatibility testingFirst step
    Why
    Prepare transfusion and assess haemoglobin and platelet trends.
    Interpretation and limitations
    Early haemoglobin may remain misleadingly normal after acute loss. Transfusion during uncontrolled haemorrhage is based on physiology, ongoing loss and anticipated need, not a stable-patient restrictive threshold.
  2. 02
    Coagulation screen and Clauss fibrinogen
    Why
    Identify haemostatic deficits that require targeted replacement.
    Interpretation and limitations
    Fibrinogen normally rises in pregnancy, so a low value is concerning. BSH recommends supplementation with ongoing PPH especially below 2.0 g/L; do not give unselected fibrinogen simply because bleeding has occurred.
  3. 03
    Validated viscoelastic haemostatic testing where available
    Why
    Provide rapid additional guidance to haemostatic treatment.
    Interpretation and limitations
    Use the institution's validated device-specific algorithm alongside clinical bleeding and serial results. ROTEM or TEG thresholds are not interchangeable, and a local cut-off should not be presented as universal UK practice.
  4. 04
    Blood gas, lactate, ionised calcium and temperature
    Why
    Monitor oxygen delivery and reversible contributors to coagulopathy.

Differential diagnosis

01

Concealed postoperative haemorrhage

A woman may deteriorate after caesarean with little vaginal loss because bleeding is intra-abdominal or retroperitoneal. Abdominal findings and perfusion changes should trigger urgent assessment.

02

Uterine inversion

Shock and bleeding immediately after placental delivery may accompany an inverted fundus, sometimes visible vaginally. Reduction of the uterus is required rather than escalating uterotonics before replacement.

03

Non-haemorrhagic collapse

Sepsis, pulmonary embolism, anaphylaxis and cardiac disease can cause postpartum hypotension or hypoxia. The presence or absence of bleeding and bedside assessment guide parallel investigation.

Management

01Initial responseResuscitation and immediate haemostasisFirst stepBleeding is excessive, continuing or accompanied by physiological deterioration.+
  1. 1Call senior maternity and anaesthetic help, allocate leadership and a recorder, and alert the laboratory early when substantial replacement may be needed.
  2. 2Assess ABC, lie the woman appropriately, give oxygen for significant shock or hypoxaemia, and obtain two large-bore intravenous lines with urgent samples.
  3. 3Quantify ongoing loss, keep the woman warm and use warmed fluid judiciously while arranging blood components when indicated.
  4. 4Massage an atonic uterus, empty the bladder, give suitable uterotonics and early tranexamic acid while inspecting for trauma or retained tissue.
  5. 5Activate the major haemorrhage protocol according to ongoing bleeding, physiology and expected need; do not

Complications

01

Organ injury and transfusion morbidity

Severe shock can damage kidneys, heart and brain. Large transfusion requirements add risks that must be monitored, while prompt adequate replacement remains essential to restore oxygen delivery.

02

Hysterectomy and fertility effects

Definitive uterine surgery may be necessary when other haemostatic measures fail. Explain the reason and longer-term implications sensitively as part of recovery and follow-up.

03

Anaemia and delayed recovery

Fatigue, breathlessness and difficulty managing newborn care can persist after haemostasis. Treat iron deficiency and anaemia, assess functional recovery and provide support rather than considering the episode finished when bleeding stops.

Monitoring and follow-up

  • Assess uterine tone, ongoing visible and concealed loss and maternal perfusion repeatedly, with clear escalation after each ineffective intervention.
  • During transfusion maintain positive patient identification and watch for reactions, hypocalcaemia, hypothermia and circulatory overload.
  • Once bleeding stops, reassess haemoglobin in context, select oral or intravenous iron or further transfusion according to symptoms and recovery, and review feeding support.
  • Offer a later discussion explaining the cause, treatment and future pregnancy implications, with psychological follow-up when needed.

Special situations

Treatment depends on prior prophylaxis

The current NICE uterotonic table distinguishes women given no prophylactic medicine, oxytocin, oxytocin–ergometrine or carbetocin. Record previous drugs and times so the next treatment is a reasoned choice rather than an automatic repeated sequence.

Carbetocin is not rescue treatment

Carbetocin can be used for prevention in appropriate birth contexts, but the December 2024 NICE amendment removed it from the PPH treatment table. Do not infer a rescue dose from its prophylactic role.

No universal obstetric component ratio

BSH states that the optimal red-cell-to-plasma ratio in PPH is unknown. Emergency packs provide logistical speed, followed by patient-specific adjustment; a trauma ratio should not be taught as a definitive requirement for every obstetric bleed.

A newer component does not replace the pathway

The July 2025 BSH addendum permits combined leucocyte-depleted red cells and plasma where available for major bleeding. For non-O or unknown-group recipients, it specifies a maximum of four units before switching to standard components; that ABO-based cap does not apply to confirmed group O recipients. Blood-bank compatibility decisions, haemostatic testing and patient-specific component selection remain essential.

Common pitfalls

  1. 01

    Waiting for a stable-patient haemoglobin threshold in active haemorrhagic shock can delay needed red-cell resuscitation.

  2. 02

    Giving ergometrine despite pre-eclampsia or overlooking carboprost's pulmonary risks exposes the woman to preventable harm.

  3. 03

    Treating the maximum permitted carboprost total as a requirement before surgery prolongs ineffective medical management.

  4. 04

    Assuming a firm fundus excludes serious PPH misses trauma, retained placental tissue and coagulation failure.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Choosing an additional uterotonic

A woman has atonic PPH despite oxytocin. She has severe pre-eclampsia with blood pressure 174/112 mmHg and no asthma, pulmonary, cardiac, renal or hepatic disease. Which listed medicine should be avoided because of the hypertensive condition?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status9 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NICE NG235: current postpartum haemorrhage recommendations
  • RCOG Green-top 52: prevention and management of PPH
  • BSH: haematological management of major haemorrhage
  • BSH July 2025 addendum: combined red cells and plasma
  • Oxytocin 10 IU/mL concentrate: UK SmPC
  • Ergometrine injection: UK SmPC
  • Hemabate carboprost: UK SmPC
  • WHO 2025 consolidated PPH guidance: early tranexamic acid
  • All Wales PPH guideline: April 2025 national pathway

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

  • Use the four Ts to organise causes: tone, trauma, tissue and thrombin.
  • Massage an atonic uterus, empty the bladder and give an appropriate uterotonic.
  • Choose uterotonics according to what was already given, contraindications and current NICE guidance.
  • Give intravenous tranexamic acid early for PPH alongside uterotonics and other treatment.
  • Do not wait for a haemoglobin threshold or a completed transfusion count to activate major haemorrhage care.
  • Escalate to mechanical or surgical control promptly when bleeding persists.
  • Interpretation and limitations
    Hypothermia, acidosis and hypocalcaemia worsen clotting and cardiovascular function. Correct demonstrated abnormalities while controlling the source, and avoid assuming that blood component delivery alone has restored physiology.
  • 05
    Examination under anaesthesia and targeted imaging
    Why
    Identify retained tissue, tears or concealed postoperative bleeding.
    Interpretation and limitations
    Surgical assessment may be both diagnostic and therapeutic. Ultrasound can help selected stable cases but should not delay theatre in an unstable woman or be treated as perfectly specific for retained tissue.
  • wait to satisfy a retrospective massive-transfusion definition.
    02Persistent bleedingEscalate source controlEscalationBleeding continues despite initial uterotonics and bedside measures.+
    1. 1DefinitiveUse bimanual uterine compression as a bridge for atony while moving to examination and definitive treatment.
    2. 2Inspect and repair genital tract trauma and assess placental completeness; suspected placenta accreta requires senior management without forceful separation.
    3. 3For persistent atony, consider uterine balloon tamponade with appropriate monitoring and readiness for further surgery.
    4. 4EscalationEscalate to compression sutures, vascular control, embolisation when clinically feasible, or hysterectomy according to the source, stability and expertise.
    5. 5DefinitiveDo not continue repeated unsuccessful conservative measures while the woman's condition deteriorates and definitive surgery is required.
    03TransfusionProvide targeted haemostatic resuscitationBlood loss or shock warrants emergency red cells and haemostatic support.+
    1. 1Request emergency-release red cells when waiting for full compatibility would be unsafe, following strict identity checks and laboratory direction.
    2. 2Use the local emergency component pack while results are pending, then individualise plasma, platelets and fibrinogen replacement with haematology input.
    3. 3Repeat coagulation and platelet testing approximately every thirty to sixty minutes during major ongoing bleeding, more urgently when the clinical course requires.
    4. 4Monitor temperature and ionised calcium, consider cell salvage when appropriate expertise is available, and communicate when bleeding has stopped so unnecessary packs are not issued.
    5. 5After haemostasis, review anaemia treatment, fluid balance, thromboprophylaxis timing and ongoing critical-care requirements.
    Key medicines and prescribing safety5 treatments · regimens, roles and cautions+
    Stimulates uterine contraction as part of treatment selected according to preceding prophylaxis and response.

    Oxytocin: product-specific treatment example

    For the 10 IU/mL concentrate cited, give 5 IU diluted in physiological electrolyte solution by intravenous infusion over 5 minutes; severe cases may need 5–20 IU in 500 mL electrolyte diluent, titrated to control atony.

    This is the cited product's regimen, not a universal instruction for every formulation or local infusion. Avoid rapid undiluted intravenous bolus dosing; monitor hypotension, tachycardia, fluid balance and hyponatraemia risk, and stop or review once control is achieved.

    Provides sustained uterine contraction when appropriate after reviewing previous uterotonics.

    Ergometrine injection

    A commonly used acute PPH dose is 500 micrograms intramuscularly; the cited SmPC permits 200–500 micrograms IM or 250–500 micrograms by slow IV injection for severe atonic haemorrhage.

    Avoid in severe hypertension, pre-eclampsia or eclampsia, severe cardiac, hepatic or renal disease, occlusive vascular disease and sepsis. Check non-atonic causes before repeating; NICE allows selected repeat ergot treatment if other medicines are unavailable, rather than routine repeated dosing.

    Treats refractory atonic postpartum haemorrhage when appropriate uterotonics have been insufficient or alternatives are unsuitable.

    Carboprost: Hemabate

    Give 250 micrograms by deep intramuscular injection; further doses are usually about 90 minutes apart, shortened in severe cases to no less than 15 minutes; maximum 2 mg in eight doses.

    Never give intravenously. Active cardiac, pulmonary, renal or hepatic disease is contraindicated; a history of asthma requires special caution because of bronchoconstriction risk. Monitor gastrointestinal effects, pyrexia and cardiorespiratory status; do not

    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
    postpone surgery to exhaust eight doses.
    Additional uterotonic treatment, potentially used earlier when intravenous access is unavailable.

    Misoprostol for PPH

    NICE includes 800 micrograms sublingually or rectally as an acute dose; reassess bleeding promptly and escalate treatment if inadequate.

    This PPH use is off label. Fever, shivering and gastrointestinal effects are common; it does not replace prompt transfer, transfusion or surgery when required.

    Reduces fibrinolytic bleeding and complements uterotonics and direct haemorrhage control.

    Tranexamic acid

    Give 1 g intravenously over 10 minutes as soon as PPH is recognised, within 3 hours of birth; a further 1 g may be given for bleeding persisting after 30 minutes or recurring within 24 hours of completing the first dose.

    The birth-based window follows WHO guidance; BSH describes treatment within three hours of bleeding onset. Use intravenously only, assess contraindications and renal function, and keep it physically distinct from spinal medicines to prevent fatal intrathecal administration.